TrialJournal for immunotherapy of cancer2021

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.

Kuimin Mei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.